Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | HTR7 | P34969 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxypertine SCHEMBL2463001 | 1.00 | DRD2 (1.00) | DRD2HTR1ANR1I2ADRB1ADRA2A | |
| Oxypertine SCHEMBL31153315 | 1.00 | DRD2 (1.00) | DRD2HTR1ANR1I2ADRB1ADRA2A | |
| Oxypertine SCHEMBL3440995 | 0.99 | DRD2 (0.98) | DRD2HTR1ANR1I2ADRB1ADRA2A | |
| Oxypertine SCHEMBL3478579 | 0.99 | DRD2 (0.98) | DRD2HTR1ANR1I2ADRB1ADRA2A | |
| Oxypertine SCHEMBL5069690 | 0.99 | DRD2 (0.98) | DRD2HTR1ANR1I2ADRB1ADRA2A | |
| Oxypertine SCHEMBL20270862 | 0.99 | DRD2 (0.98) | DRD2HTR1ANR1I2ADRB1ADRA2A | |
| Oxypertine SCHEMBL21268763 | 0.97 | HTR1A (0.94) | DRD2HTR1ANR1I2ADRB1ADRA2A | |
| Oxypertine SCHEMBL2837214 | 0.97 | DRD2 (0.94) | DRD2HTR1ANR1I2ADRB1ADRA2A | |
| Oxypertine SCHEMBL7527152 | 0.94 | HTR1A (0.88) | DRD2HTR1ANR1I2ADRB1ADRA2A | |
| SCHEMBL2615395 | 0.92 | DRD2 (0.84) | DRD2HTR1ANR1I2ADRB1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 197071 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4674482-A2 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS ASSOCIATED WITH NEURODEGENERATIVE DISEASE OR IMPULSIVE SYMPTOMS ASSOCIATED WITH MENTAL DISEASE CONTAINING BREXPIPRAZOLE OR SALT THEREOF | Otsuka Pharmaceutical Co., Ltd. (JP) | 2026-01-07 | — | — | EP | claimed |
| EP-4618973-A1 | METHODS OF SWITCHING NEUROPSYCHIATRIC MEDICATIONS USING ULOTARONT | Sumitomo Pharma America, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| US-20250179064-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | AUSPEX PHARMACEUTICALS LLC | 2025-06-05 | — | — | US | claimed |
| US-20250099459-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS ASSOCIATED WITH NEURODEGENERATIVE DISEASE OR IMPULSIVE SYMPTOMS ASSOCIATED WITH MENTAL DISEASE CONTAINING BREXPIPRAZOLE OR SALT THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-03-27 | — | — | US | claimed |
| US-20240241134-A1 | NOVEL BIOLOGICAL MARKERS IN THE DIAGNOSIS OF ENDOMETRIOSIS | YEDITEPE UNIVERSITESI (TR) | 2024-07-18 | — | — | US | claimed |
| US-20240238239-A1 | METHODS AND COMPOSITIONS FOR POTENTIATING STEM CELL THERAPIES | OJAI ENERGETICS PBC | 2024-07-18 | — | — | US | claimed |
| WO-2024151814-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY OF TGFβ | REGENERON PHARMACEUTICALS, INC. (US) | 2024-07-18 | — | — | WO | claimed |
| US-20240238368-A1 | PEPTIDE FOR PREVENTING AND TREATING FIBROSIS | NIBEC CO., LTD. (KR) | 2024-07-18 | — | — | US | claimed |
| WO-2024151991-A1 | RNAI AGENTS FOR INHIBITING INFLUENZA A VIRAL GENE EXPRESSION, COMPOSITIONS THEREOF, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2024-07-18 | — | — | WO | claimed |
| US-20240240360-A1 | ANTIBODY LIBRARIES WITH MAXIMIZED ANTIBODY DEVELOPABILITY CHARACTERISTICS | RULES-BASED MEDICINE INC. (US) | 2024-07-18 | — | — | US | claimed |
| WO-1991006324-A1 | ACTIVE SUBSTANCE COMPLEX FOR THE PRODUCTION OF BIOLOGICAL PARTS, ESPECIALLY ORGANS FOR LIVING ORGANISMS; PROCESS FOR ITS PRODUCTION AND ITS USE | SCHMIDT KARLHEINZ (DE) | 1991-05-16 | — | — | WO | claimed |
| EP-0419099-A1 | Proteins having anticoagulant properties | MERCK & CO. INC. (US) | 1991-03-27 | — | — | EP | claimed |
| WO-1991002755-A1 | FIBULIN | LA JOLLA CANCER RESEARCH FOUNDATION (US) | 1991-03-07 | — | — | WO | claimed |
| WO-1990014443-A1 | CO-EXPRESSION OF HETEROMERIC RECEPTORS | HUSE WILLIAM D (US) | 1990-11-29 | — | — | WO | claimed |
| WO-1990006953-A2 | METHOD FOR PREPARING WATER SOLUBLE POLYPEPTIDES | GENENTECH, INC. (US) | 1990-06-28 | — | — | WO | claimed |
| WO-1990003983-A1 | PEPTIDES AND ANTIBODIES THAT INHIBIT INTEGRIN-LIGAND BINDING | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1990-04-19 | — | — | WO | claimed |
| WO-1990002556-A1 | METHODS FOR MODIFYING THE BINDING OF CELL ADHESION RECEPTORS | LA JOLLA CANCER RESEARCH FOUNDATION (US) | 1990-03-22 | — | — | WO | claimed |
| US-4690824-A | Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range | REDI-ROWELL, INC. (US) | 1987-09-01 | — | — | US | claimed |
| US-4175119-A | Composition and method to prevent accidental and intentional overdosage with psychoactive drugs | PORTER GARRY L | 1979-11-20 | — | — | US | claimed |
| US-4089853-A | Process for the preparation of cis-5,6-dimethoxy-2-methyl-3-[2-(4-phenyl-1-piperazinyl)-ethyl]indoline | AMERICAN CYANAMID COMPANY (US) | 1978-05-16 | — | — | US | claimed |